Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Cardiology
•
Cardiovascular Imaging
What are some high-risk TTE features that would prompt you to consider serial TTEs to look for LV thrombus formation post-MI, and how frequently would you image these patients?
Related Questions
Should there be age cut-off considerations when ordering TTEs with bubble routinely as part of stroke work-up?
What is the role of MRI in assessing the risk of embolism in patients with persistent left ventricular thrombus following myocardial infarction?
What are some TTE findings that suggest worsening function of a bioprosthetic AVR that would require further surveillance or diagnostic imaging?
What is a reasonable imaging modality for older patients with pAfib already on systemic anticoagulation outpatient but presenting with suspected cardioembolic stroke and TTE without evidence of LV thrombus?
What are reasonable next steps in the work-up of suspected ATTR amyloidosis if the PYP scan is equivocal, in light of the potential risks of endomyocardial biopsy?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
Would it be reasonable to begin considering GLP1 RAs or finerenone for patients with heart failure with recovered LVEF in light of recent trials such as SELECT and FINEARTS-HF showing some success in HFpEF and HFmrEF populations?
What is the clinical significance of intracardiac vacuum(s) noted during diastole, especially in terms of the diagnosis and management of diastolic dysfunction?
Would you consider sotalol to be a suitable non-selective beta blocker for primary prevention of variceal bleeding in a patient who requires sotalol for treatment of arrhythmia in the setting of Fontan-associated liver disease and clinically significant portal hypertension?
How do you consider and approach transition to hospice in a patient with HFrEF who does not appear to tolerate GDMT?
